Bionomics Limited (BNO)

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today » it's FREE! Already a member? Login now!

General Information
Company Name: Bionomics Limited
Stock Code: BNO
GICS Sub-Industry: Biotechnology
Market Cap ($M): 205
Equiv. Shares (M): 417

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
 $ 0.490 $ 0.490 $ 0.490 $ 0.480 $ 0.480 36,741 $ 0.010  2.083 %

Current Broker Consensus Recommendation more
Recommendation: Buy (2)
Recommendation Date: 12th Nov 2014
Brokers Surveyed: 1

Company Overview

Business Description:
Bionomics Limited (BNO) is an Australian biotechnology company focused on the discovery and development of cancer, central nervous system disorders such as anxiety, depression and Alzheimer's Disease. BNO partners with pharmaceutical companies to get the drugs through the later stages of development and into the market.

Strategy Analysis:
BNO seeks to develop compounds to successful proof of concept in human clinical trials. The company is open to partnership at all stages of development. Additionally, BNO is open to in-licensing proposals that are in alignment with the company's overall therapeutic focus in cancer, inflammatory disorders and CNS diseases.

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2016  F -- 7.4 31.1 6.6 -- 0.0 --
2015  F -- 5.6 631.2 8.7 -- 0.0 --
2014  A 3.2 0.8 -- 79.8 0.0 0.0 --
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F
Bionomics (BNO) $200 M -- 6.3117 0.3108 62.3377 8.5258 6.5041 0.00 0.00 0.00
CSL (CSL) $37,765 M 0.0899 0.2412 0.0806 27.8293 22.4222 20.7496 1.51 1.81 2.01
Mesoblast (MSB) $1,319 M -- -- -- -- -- -- 0.00 0.00 0.00
Starpharma (SPL) $163 M -- -- -0.9147 -- 10.8742 127.5000 0.00 0.00 0.00
Sirtex Medical (SRX) $1,481 M 0.2906 0.5153 0.3538 63.4383 41.8664 30.9254 0.53 0.66 1.07

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
BNO 0.76 17.8 4.56 0.08 10.56
Market 1.13 13.6 1.00 1.02 3.01
Sector 0.81 18.0 2.67 1.23 7.08

Name Position Start Date
Dr Deborah Ann Rathjen Chief Executive Officer,Managing Director 21 June 2000
Mr Trevor Tappenden Non-Executive Director 15 September 2006
Dr Errol De Souza Non-Executive Director 28 February 2008
Dr Jonathan Lim Non-Executive Director 14 September 2012
Mr Graeme Kaufman Non-Executive Director,Non-Executive Chairman 18 September 2012

Name Position
Melanie Young Chief Financial Officer,Company Secretary
Jose Iglesias Chief Medical Officer
Emile Andriambeloson Head of Research, Neurofit
Peter Chu Vice President US Operations & Cancer Biology

Substantial Shareholders
Holding Name
24,000,000 (5.75%) Ausbil Dexia Limited
40,187,873 (9.63%) Link Traders (Aust) Pty Limited
21,642,425 (5.19%) Australian National University
24,241,071 (5.81%) John Leaver

Calendar of Events
Date Event
09 October 2015 Report (Annual)
18 August 2015 Report (Prelim)
17 February 2015 Report (Interim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at


Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Active Investing and Trading

An educational booklet with information on how analysis and risk management can enhance your share investments.

More details...


Australian Share Market - Close Up

CMC Markets 11/11/2014 | The Australian share market is in a decision zone - and trading from here may set the direction for the rest of the year.

Prices slashed - everything must go!

Nick Swales, Regional Director, Newcastle Office, Rathbones 27/10/2014 | “If you want to have a better performance than the crowd, you must do things differently from the crowd.” Sir John Templeton.

Aussie share market bulls now have company

Ric Spooner (Chief Market Analyst, CMC Markets) 20/10/2014 | Today, Australian investors will not have to go it alone buying stocks as they did for much of last week. Bargain hunters this morning will be supported by the morale boosting encouragement of a 3% turnaround in the German Dax and a 264 point rally in the Dow Jones.

The Importance of Ignoring the Noise of the Market

Carl Richards, director of investor education at the BAM Alliance 17/10/2014 | “As odd as it may sound, the sooner you start treating your investments like you treat life, the happier you’ll be with the outcome.”

You only dance twice

William H. Gross, Janus Capital Group 16/10/2014 | “Financial markets are artificially priced. In the bond market, there is nothing normal about a three year German Bund yielding “minus” 10 basis points.”

The Big Picture - Australia 200 Index

CMC Markets 8/10/2014 | Share market indices around the globe are breaking down. While analysts cast around for reasons, it’s clear that a time factor is in play. Simply put, many investors “feel” a correction is overdue. How low could it go?


Sponsored Links